Search for a command to run...
Walpar Nutritions Ltd. demonstrates impressive growth metrics, particularly in revenue and earnings, positioning it favorably compared to its peers. However, its valuation ratios suggest caution, as the company is still in the early stages of profitability. While several peers exhibit strong performance, some are overvalued based on their earnings potential, making Walpar a potential value pick within the sector.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
WALPAR | - | - | 0.00 | 14.23% | 0.59 |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |